Antithrombotic Strategy in Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Choosing antithrombotic regimens for patients with atrial fibrillation (AF) who underwent percutaneous coronary intervention (PCI) with stent placement is challenging. Until recently, the guidelines recommended warfarin-based triple therapy, which causes frequent major bleeding events in up to 12% of patients during the first year of treatment. The WOEST trial, however, revealed that dual therapy, by without aspirin, resulted in significantly lower bleeding risks with similar thromboembolic events to triple therapy. Subsequently, efforts to seek the optimal dual therapy regimens, especially with the combination of a non-vitamin K antagonist oral anticoagulant (NOAC), were initiated. This review highlights the evidence for dual therapy using an NOAC for patients with AF who underwent PCI, with an emphasis on reduced bleeding risk.
Abstract
Choosing antithrombotic regimens for patients with atrial fibrillation (AF) who underwent percutaneous coronary intervention (PCI) with stent placement is challenging. Until recently, the guidelines recommended warfarin-based triple therapy, which causes frequent major bleeding events in up to 12% of patients during the first year of treatment. The WOEST trial, however, revealed that dual therapy, by without aspirin, resulted in significantly lower bleeding risks with similar thromboembolic events to triple therapy. Subsequently, efforts to seek the optimal dual therapy regimens, especially with the combination of a non-vitamin K antagonist oral anticoagulant (NOAC), were initiated. This review highlights the evidence for dual therapy using an NOAC for patients with AF who underwent PCI, with an emphasis on reduced bleeding risk.
참고문헌 (23)
- Kralev S, "Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography", PLoS One, 6, pp.e24964~ (2011)
- Windecker S, "2014 ESC", EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), 2014, pp.35, 2541~2619
- Lip GY, "Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and", or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS), 2014, pp.35, 3155~3179
- Paikin JS, "Triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents", Circulation, 121, pp.2067~2070 (2010)
- Hansen ML, "Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation", Arch Intern Med, 170, pp.1433~1441 (2010)
- Lamberts M, "Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study", Circulation, 126, pp.1185~1193 (2012)
- Sørensen R, "Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data", Lancet, 374, pp.1967~1974 (2009)
- Dewilde WJ, "Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial", Lancet, 381, pp.1107~1115 (2013)
- Patel MR, "Rivaroxaban versus warfarin in nonvalvular atrial fibrillation", N Engl J Med, 365, pp.883~891 (2011)
- Connolly SJ, "Dabigatran versus warfarin in patients with atrial fibrillation", N Engl J Med, 361, pp.1139~1151 (2009)
- Gibson CM, "Prevention of bleeding in patients with atrial fibrillation undergoing PCI", N Engl J Med, 375, pp.2423~2434 (2016)
- Mega JL, "Rivaroxaban in patients with a recent acute coronary syndrome", N Engl J Med, 366, pp.9~19 (2012)
- Steffel J, "The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation", Eur Heart J, 39, pp.1330~1393 (2018)
- Mehta SR, "2018Canadian Cardiovascular Society", Canadian Association of interventional cardiology focused update of the guidelines for the use of antiplatelet therapy, 2018, pp.34, 214~233
- Angiolillo DJ, "Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention", Circulation, 138, pp.527~536 (2018)
- Cannon CP, "Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation", N Engl J Med, 377, pp.1513~1524 (2017)
- Piccini JP, "Triple therapy for atrial fibrillation after PCI", N Engl J Med, 377, pp.1580~1582 (2017)
- Golwala HB, "Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials", Eur Heart J, 39, pp.1726~1735a (2018)
- Cavallari I, "Meta-analysis comparing the safety and efficacy of dual versus triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention", Am J Cardiol, 121, pp.718~724 (2018)
- Neumann FJ, "‘Ten commandments’ for the 2018 ESC", EACTS Guidelines on myocardial revascularization, 2018, pp.39, 3759~
- Hori M, "Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation – the J-ROCKET AF study –", Circ J, 76, pp.2104~2111 (2012)
- Vranckx P, "Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: rationale and design of the ENTRUST-AF PCI trial", Am Heart J, 196, pp.105~112 (2018)
- Lopes RD, "An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and", or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial, 2018, pp.200, 17~23